Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106611022 | 10661102 | 2 | F | 20141209 | 20160621 | 20141218 | 20160701 | EXP | AU-ALEXION PHARMACEUTICALS INC-A201404700 | ALEXION | 6.00 | YR | M | Y | 0.00000 | 20160701 | CN | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106611022 | 10661102 | 1 | PS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 600 MG, QW | 125166 | 600 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | /wk | ||||||
| 106611022 | 10661102 | 2 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 300 MG, QW | 125166 | 300 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | /wk | ||||||
| 106611022 | 10661102 | 3 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 600 MG, Q2W | 125166 | 600 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | ||||||
| 106611022 | 10661102 | 4 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 600 MG, QW | 125166 | 600 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | /wk | ||||||
| 106611022 | 10661102 | 5 | C | CIDOFOVIR. | CIDOFOVIR | 1 | Unknown | 0 | |||||||||||
| 106611022 | 10661102 | 6 | C | HEPARIN | HEPARIN SODIUM | 1 | Unknown | 0 | |||||||||||
| 106611022 | 10661102 | 7 | C | LASIX | FUROSEMIDE | 1 | Unknown | UNK | 0 | ||||||||||
| 106611022 | 10661102 | 8 | C | HYDRALAZINE | HYDRALAZINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 106611022 | 10661102 | 9 | C | NIFEDIPINE. | NIFEDIPINE | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 106611022 | 10661102 | 10 | C | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | 60 MG/KG, UNK | 0 | 60 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106611022 | 10661102 | 1 | Haemolytic uraemic syndrome |
| 106611022 | 10661102 | 5 | Product used for unknown indication |
| 106611022 | 10661102 | 6 | Product used for unknown indication |
| 106611022 | 10661102 | 7 | Oliguria |
| 106611022 | 10661102 | 8 | Venoocclusive disease |
| 106611022 | 10661102 | 9 | Product used for unknown indication |
| 106611022 | 10661102 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106611022 | 10661102 | DE |
| 106611022 | 10661102 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106611022 | 10661102 | Drug ineffective | |
| 106611022 | 10661102 | Gastrointestinal haemorrhage | |
| 106611022 | 10661102 | Multiple organ dysfunction syndrome | |
| 106611022 | 10661102 | Pancreatitis viral | |
| 106611022 | 10661102 | Renal failure | |
| 106611022 | 10661102 | Thrombotic microangiopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 106611022 | 10661102 | 1 | 201410 | 0 | ||
| 106611022 | 10661102 | 2 | 20141107 | 0 |